ORAMED PHARMACEUTICALS INC. (ORMP) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $495.00K; Additional Paid in Capital, Common StockUSD $323.94M; Retained Earnings (Accumulated Deficit)USD $-6.96M; Stockholders' Equity Attributable to ParentUSD (m).
- 2026-03-31: Common Stock, Value, IssuedUSD $491.00K; Additional Paid in Capital, Common StockUSD $322.91M; Retained Earnings (Accumulated Deficit)USD $-85.12M; Stockholders' Equity Attributable to ParentUSD (m).
- 2025-12-31: Common Stock, Value, IssuedUSD $472.00K; Additional Paid in Capital, Common StockUSD $322.71M; Retained Earnings (Accumulated Deficit)USD $-123.44M; Stockholders' Equity Attributable to ParentUSD $199.74M.
- 2025-09-30: Common Stock, Value, IssuedUSD $490.00K; Additional Paid in Capital, Common StockUSD $325.37M; Retained Earnings (Accumulated Deficit)USD $-122.58M; Stockholders' Equity Attributable to ParentUSD $203.28M.
ORAMED PHARMACEUTICALS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Retired, Cost Method, Amount USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD | Noncontrolling Interest in Variable Interest Entity USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $495.00K | $323.94M | $-6.96M | (m) | $317.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $491.00K | $322.91M | $-85.12M | (m) | $238.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $472.00K | $322.71M | $-123.44M | $199.74M | $199.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $490.00K | $325.37M | $-122.58M | $203.28M | $202.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $491.00K | $325.01M | $-170.97M | $154.53M | $153.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $491.00K | $324.58M | $-184.26M | $140.81M | $139.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $480.00K | $322.40M | $-176.62M | $146.26M | $145.35M | (m) | 12 month · $53.00K | 12 month · 2.36 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $484.00K | $322.38M | $-166.43M | $156.44M | $155.52M | 3 month · $1.29M 9 month · $1.29M | 3 month · $15.00K 9 month · $42.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $488.00K | $323.38M | $-146.81M | $177.06M | $176.15M | (m) | 3 month · $15.00K 6 month · $27.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $487.00K | $322.17M | $-156.02M | $166.64M | $165.72M | (m) | 3 month · $12.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $485.00K | $320.89M | $-157.56M | $163.82M | $162.89M | (m) | 12 month · $165.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $484.00K | $319.54M | $-170.89M | $149.13M | $148.23M | (m) | 3 month · $51.00K 9 month · $151.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $484.00K | (m) | $-167.67M | $151.55M | $150.66M | (m) | 3 month · $50.00K 6 month · $100.00K | (m) | $318.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $481.00K | (m) | $-166.48M | $150.97M | $150.15M | (m) | 3 month · $50.00K | (m) | $316.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $476.00K | $314.42M | $-163.08M | $151.81M | $151.16M | (m) | 12 month · $390.00K | (m) | $314.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $470.00K | (m) | $-154.54M | $153.81M | $153.15M | (m) | 3 month · $192.00K 9 month · $192.00K | (m) | $307.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $463.00K | (m) | $-147.48M | $153.70M | $153.04M | (m) | (m) | (m) | $300.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $463.00K | (m) | $-136.94M | $162.35M | $162.22M | (m) | (m) | (m) | $298.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $459.00K | (m) | $-126.52M | $166.45M | $166.61M | (m) | (m) | (m) | $292.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-11-30 | $458.00K | (m) | $-122.74M | $170.16M | $170.69M | (m) | (m) | (m) | $292.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | $123.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 33.33K |
| 2021-08-31 | $424.00K | (m) | $-114.85M | $115.77M | $116.52M | (m) | (m) | (m) | $230.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.50M | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $90.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-05-31 | $366.00K | (m) | $-108.00M | $68.12M | $69.19M | (m) | (m) | (m) | $175.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.50M | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $65.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-02-28 | $339.00K | (m) | $-102.79M | $49.44M | $49.44M | (m) | (m) | (m) | $151.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | $38.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-11-30 | $286.00K | (m) | $-98.18M | $28.21M | $28.21M | (m) | (m) | (m) | $126.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-08-31 | $284.00K | $125.21M | $-92.61M | $32.88M | $32.88M | (m) | (m) | (m) | $125.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-05-31 | $279.00K | $123.45M | $-89.62M | $34.11M | $34.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-02-29 | $214.00K | $103.21M | $-87.33M | $16.09M | $16.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-11-30 | $209.00K | $100.60M | $-83.65M | $17.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-08-31 | $208.00K | $100.29M | $-81.10M | $19.39M | $19.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-05-31 | $207.00K | $100.17M | $-78.82M | $21.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-02-28 | $207.00K | $99.89M | $-74.75M | $25.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-11-30 | $207.00K | $99.70M | $-71.05M | $28.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-08-31 | $207.00K | $99.43M | $-69.22M | $31.11M | (m) | (m) | (m) | (m) | (m) | $702.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-05-31 | $172.00K | $82.58M | $700.00K | $16.66M | (m) | (m) | (m) | (m) | (m) | $198.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-02-28 | $171.00K | $81.94M | $-61.94M | $20.48M | (m) | (m) | (m) | (m) | (m) | $313.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-11-30 | $170.00K | $80.87M | $-59.03M | $22.74M | (m) | (m) | (m) | (m) | (m) | $727.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-08-31 | $163.00K | $75.17M | $-56.50M | $19.24M | (m) | (m) | (m) | (m) | (m) | $401.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-05-31 | $159.00K | $72.95M | $-53.80M | $19.81M | (m) | (m) | (m) | (m) | (m) | $497.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-02-28 | $159.00K | $72.79M | $-51.84M | $21.32M | (m) | (m) | (m) | (m) | (m) | $211.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-11-30 | $158.00K | $72.44M | $-48.65M | $23.99M | (m) | (m) | (m) | (m) | (m) | $43.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-08-31 | $157.00K | $71.94M | $-46.02M | $26.19M | (m) | (m) | (m) | (m) | (m) | $106.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-05-31 | $157.00K | (m) | $-41.26M | $30.98M | (m) | (m) | (m) | (m) | $71.77M | $314.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-02-29 | $157.00K | $71.58M | $-39.26M | $32.70M | (m) | (m) | (m) | (m) | (m) | $230.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-11-30 | $138.00K | $59.69M | $-37.44M | $22.54M | (m) | (m) | (m) | (m) | (m) | $152.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-08-31 | $138.00K | $59.18M | $-35.05M | $24.83M | (m) | (m) | (m) | (m) | $59.18M | $558.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-05-31 | $129.00K | $53.97M | $-32.94M | $21.33M | (m) | (m) | (m) | (m) | (m) | $163.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-02-28 | $129.00K | $53.46M | $-31.35M | $22.34M | (m) | (m) | (m) | (m) | (m) | $100.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-11-30 | $129.00K | $53.19M | $-29.72M | $23.70M | (m) | (m) | (m) | (m) | (m) | $93.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-08-31 | $121.00K | $48.04M | $-27.82M | $20.79M | (m) | (m) | (m) | (m) | (m) | $452.00K | (m) | (m) | 12 month · $1.47M | (m) | (m) | (m) | (m) | (m) |
| 2014-05-31 | $119.46K | $47.57M | $-26.19M | $21.97M | (m) | (m) | (m) | (m) | (m) | $467.97K | 9 month · $1.00M | 9 month · $36.43K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-02-28 | $117.30K | $46.73M | $-24.36M | $23.33M | (m) | (m) | (m) | (m) | (m) | $846.99K | 6 month · $276.12K | 6 month · $57.02K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-11-30 | $95.36K | $30.12M | $-23.25M | $7.31M | (m) | (m) | (m) | (m) | (m) | $334.17K | 3 month · $200.86K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-08-31 | $95.00K | $29.86M | $-22.12M | $8.13M | (m) | (m) | (m) | (m) | (m) | $304.00K | 12 month · $562.97K | 12 month · $156.25K | 12 month · $719.00K | (m) | 12 month · $918.00K | (m) | (m) | (m) |
| 2013-05-31 | $86.70K | $25.27M | $-21.33M | $4.16M | (m) | (m) | (m) | (m) | (m) | $131.92K | 9 month · $487.03K | (m) | (m) | (m) | 9 month · $917.81K | (m) | (m) | (m) |
| 2013-02-28 | $86.66K | $24.99M | $-20.08M | $5.25M | (m) | (m) | (m) | (m) | (m) | $244.51K | (m) | (m) | (m) | (m) | 6 month · $917.81K | (m) | (m) | (m) |
| 2012-11-30 | $86.50K | $24.78M | $-18.85M | $6.25M | (m) | (m) | (m) | (m) | (m) | $235.87K | 3 month · $190.19K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-08-31 | $80.08K | $21.59M | $-17.89M | $3.78M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $200.87K | 12 month · $70.29K | 12 month · $271.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-05-31 | $70.40K | $18.45M | $-16.56M | $1.97M | (m) | (m) | (m) | (m) | (m) | $15.87K | 9 month · $80.49K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-02-29 | $70.19K | $18.34M | $-16.01M | $2.40M | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $66.14K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-11-30 | $70.10K | $18.28M | $-15.03M | $3.32M | (m) | (m) | (m) | (m) | (m) | $-4.22K | 3 month · $44.79K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-08-31 | $70.10K | $18.20M | $-14.55M | $3.72M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $502.59K | 12 month · $26.73K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-08-31 | (m) | (m) | (m) | $830.27K | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $690.88K 101 month · $3.55M | 12 month · $116.94K | (m) | 101 month · $108.00K | (m) | 101 month · $18.99K | (m) | (m) |
| 2009-08-31 | (m) | (m) | (m) | $2.75M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $436.02K | 12 month · $117.17K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-08-31 | (m) | (m) | (m) | $4.59M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $459.47K | 12 month · $203.98K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-08-31 | (m) | (m) | (m) | $513.13K | (m) | (m) | (m) | (m) | (m) | (m) | 65 month · $1.97M | 65 month · $177.78K | (m) | 65 month · $108.00K | (m) | 65 month · $18.99K | (m) | (m) |
| 2002-04-11 | (m) | (m) | (m) | $53.70K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |